TY - JOUR
T1 - Development of IL-22-producing NK lineage cells from umbilical cord blood hematopoietic stem cells in the absence of secondary lymphoid tissue
AU - Tang, Qin
AU - Ahn, Yong Oon
AU - Southern, Peter
AU - Blazar, Bruce R.
AU - Miller, Jeffery S.
AU - Verneris, Michael R.
PY - 2011/4/14
Y1 - 2011/4/14
N2 - Human secondary lymphoid tissues (SLTs) contain interleukin-22 (IL-22)-producing cells with an immature NK phenotype. Given their location, these cells are difficult to study. We have generated large numbers of NK22 cells from hematopoietic stem cells. HSC-derived NK22 cells show a CD56 + CD117highCD94- phenotype, consistent with stage III NK progenitors. Like freshly isolated SLT stage III cells, HSC-derived NK22 cells express NKp44, CD161, CCR6, IL1 receptor, AHR, and ROR-γτ. IL-1β and IL-23 stimulation results in significant IL-22 but not interferon-γ production. Supernatant from these cells increases CD54 expression on mesenchymal stem cells. Thus, IL-22-producing NK cells can be generated in the absence of SLT. HSC-derived NK22 cells will be valuable in understanding this rare NK subset and create the opportunity for human translational clinical trials.
AB - Human secondary lymphoid tissues (SLTs) contain interleukin-22 (IL-22)-producing cells with an immature NK phenotype. Given their location, these cells are difficult to study. We have generated large numbers of NK22 cells from hematopoietic stem cells. HSC-derived NK22 cells show a CD56 + CD117highCD94- phenotype, consistent with stage III NK progenitors. Like freshly isolated SLT stage III cells, HSC-derived NK22 cells express NKp44, CD161, CCR6, IL1 receptor, AHR, and ROR-γτ. IL-1β and IL-23 stimulation results in significant IL-22 but not interferon-γ production. Supernatant from these cells increases CD54 expression on mesenchymal stem cells. Thus, IL-22-producing NK cells can be generated in the absence of SLT. HSC-derived NK22 cells will be valuable in understanding this rare NK subset and create the opportunity for human translational clinical trials.
UR - http://www.scopus.com/inward/record.url?scp=79954609836&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79954609836&partnerID=8YFLogxK
U2 - 10.1182/blood-2010-09-303081
DO - 10.1182/blood-2010-09-303081
M3 - Article
C2 - 21310921
AN - SCOPUS:79954609836
SN - 0006-4971
VL - 117
SP - 4052
EP - 4055
JO - Blood
JF - Blood
IS - 15
ER -